drugset / Trial / NCT03593902
Cardiac Safe Transplants for Systemic Sclerosis
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to treat systemic sclerosis (scleroderma) patients with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy that is less toxic to your heart.
Timeline
- Start
- 2018-05-17
- Primary completion
- 2019-10-03
- Completion
- 2019-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Stem Cells | Cell therapy | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Fludarabine | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |
| Subject | rATG | Protein / enzyme biologic | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | G-CSF | Protein / enzyme biologic | — | — |
| Background | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | Intravenous |
| Background | Methylprednisolone | Other / unclassified | — | — |